Advancing preclinical cancer models to assess clinically relevant outcomes

Cancer models are indispensable research tools for elucidating the mechanisms involved in tumor onset, progression and treatment resistance. They are key in evaluating therapeutics prior clinical trials. In this editorial, we invite contributions for a BMC Cancer's Collection of articles addressing 'Advances in pre-clinical cancer models' towards relivable outcomes at the preclinical stage.

Automated summary

Cancer models play a crucial role in understanding the mechanisms of tumor onset, progression, and treatment resistance, and are essential for evaluating therapies before clinical trials. This editorial invites contributions for a BMC Cancer Collection on 'Advances in pre-clinical cancer models' aiming for reliable preclinical outcomes.